Biomarin Pharmaceutical (BMRN) EBIT: 2009-2025
Historic EBIT for Biomarin Pharmaceutical (BMRN) over the last 14 years, with Sep 2025 value amounting to -$46.7 million.
- Biomarin Pharmaceutical's EBIT fell 141.00% to -$46.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $615.5 million, marking a year-over-year increase of 75.81%. This contributed to the annual value of $484.2 million for FY2024, which is 160.65% up from last year.
- According to the latest figures from Q3 2025, Biomarin Pharmaceutical's EBIT is -$46.7 million, which was down 116.86% from $276.9 million recorded in Q2 2025.
- Over the past 5 years, Biomarin Pharmaceutical's EBIT peaked at $276.9 million during Q2 2025, and registered a low of -$65.9 million during Q4 2021.
- In the last 3 years, Biomarin Pharmaceutical's EBIT had a median value of $88.5 million in 2024 and averaged $102.2 million.
- As far as peak fluctuations go, Biomarin Pharmaceutical's EBIT soared by 1,362.93% in 2023, and later crashed by 141.00% in 2025.
- Quarterly analysis of 5 years shows Biomarin Pharmaceutical's EBIT stood at -$65.9 million in 2021, then surged by 80.13% to -$13.1 million in 2022, then surged by 308.43% to $27.3 million in 2023, then surged by 491.69% to $161.4 million in 2024, then slumped by 141.00% to -$46.7 million in 2025.
- Its EBIT stands at -$46.7 million for Q3 2025, versus $276.9 million for Q2 2025 and $223.9 million for Q1 2025.